Molecular Mechanisms of the Hypoxic Response

缺氧反应的分子机制

基本信息

  • 批准号:
    7790056
  • 负责人:
  • 金额:
    $ 26.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2015-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The master regulator of the mammalian transcriptional response to hypoxia is the transcription factor Hypoxia Inducible Factor (HIF), the subunit of which is regulated at the level of protein turnover in an oxygen-sensitive manner. Under normoxic conditions, Prolyl Hydroxylase Domain protein (PHD) site- specifically hydroxylates HIF-(, which in turn targets HIF-( for degradation by the ubiquitin-proteasome pathway. Under hypoxic conditions, this posttranslational modification, which is inherently oxygen dependent, is inhibited, thereby allowing stabilization of HIF-(. HIF then upregulates a battery of genes involved in cellular, local, and systemic responses to hypoxia. The prototypical HIF target gene is that encoding for Erythropoietin (EPO), a glycoprotein hormone that regulates red blood cell mass in response to changes in oxygen tension. Thus, understanding HIF regulation will have implications for understanding and treating disorders of red blood cell mass regulation, such as anemia, which in turn is a significant complication seen in many clinical settings, including end stage renal disease and chemotherapy. More generally, hypoxia is a central feature of many human diseases, including coronary artery, cerebrovascular, and neoplastic disease, and therefore knowledge regarding HIF regulation will also impact our understanding of these diseases. There are three HIF-( isoforms (HIF-1(, HIF-2(, and HIF-3() and three Prolyl Hydroxylase Domain proteins (PHD1, PHD2, PHD3) that can hydroxylate them, raising the critical question of which isoforms are important for human physiology and pathophysiology. In collaboration with Professor Terence Lappin's group, we have identified a family with hereditary erythrocytosis (increased red blood cell mass) due to a G537W missense mutation in the HIF2A gene, and another family with erythrocytosis due to a P317R missense mutation in the PHD2 gene. These studies provide the first identification of hereditary mutations in any HIF or in any PHD isoform, and establish two new genetic causes of erythrocytosis. We have subsequently identified additional mutations in both genes. Our Specific Aims are to (1) study new erythrocytosis-associated HIF-2( and PHD2 mutations using in vitro assays in order to bolster our hypothesis that these proteins critically control EPO, (2) employ a Hif2a knockin mouse to model the human G537W missense mutation and examine functional consequences in vivo of dysregulation of Hif2-(, and (3) employ both a Phd2 knockin mouse for the P317R mutation, and a global conditional Phd2 knockout mouse to examine the mechanism by which Phd2 regulates red cell mass. Collectively, we anticipate that these studies will substantially increase our understanding of EPO regulation and, more broadly, our understanding of the mammalian oxygen sensing pathway. PUBLIC HEALTH RELEVANCE: This project seeks to identify and characterize the molecular pathway that leads to the control of red blood cell mass, and more generally, the response to low oxygen tension. The proposed studies focus on two proteins named Hypoxia Inducible Factor-2 and Prolyl Hydroxylase Domain protein 2 that have been implicated in controlling the hormone, Erythropoietin, that determines red cell mass. The proposed experiments will have implications for treating diseases such as anemia, in which red blood cell mass is abnormally low.
描述(申请人提供):哺乳动物对低氧的转录反应的主要调节因子是转录因子低氧诱导因子(HIF),其亚单位以氧敏感的方式在蛋白质周转水平上进行调节。在常氧条件下,Pro羟基酶结构域蛋白(PHD)定点羟化HIF-(,进而靶向HIF-),通过泛素-蛋白酶体途径降解。在低氧条件下,这种固有的氧依赖的翻译后修饰被抑制,从而使HIF-(。然后,HIF上调一系列基因,这些基因涉及细胞、局部和全身对低氧的反应。典型的HIF靶基因是编码促红细胞生成素(EPO)的基因,EPO是一种糖蛋白激素,可以调节红细胞质量,以应对氧分压的变化。因此,了解HIF的调节对于理解和治疗红细胞量调节的紊乱具有重要意义,例如贫血,而贫血又是许多临床环境中常见的重大并发症,包括终末期肾脏疾病和化疗。更广泛地说,缺氧是许多人类疾病的中心特征,包括冠状动脉、脑血管和肿瘤疾病,因此关于HIF调控的知识也将影响我们对这些疾病的理解。有三种HIF-β亚型(HIF-1、HIF-2和HIF-3)和三种脯氨酸羟基酶结构域蛋白(PhD1、PHD2、PHD3)可以羟化它们,这就提出了哪些亚型对人体生理和病理生理学具有重要意义的关键问题。与Terence Lappin教授的团队合作,我们发现了一个由于HIF2A基因G537W错义突变导致的遗传性红细胞增多症(红细胞质量增加)家族,以及另一个由于PHD2基因P317R错义突变导致的红细胞增多症家族。这些研究首次鉴定了任何HIF或任何PHD亚型的遗传性突变,并建立了两个新的红细胞增多症的遗传原因。我们随后发现了这两个基因的额外突变。我们的具体目标是(1)利用体外实验研究新的红细胞增多症相关HIF-2(和PHD2)突变,以支持我们的假设,即这些蛋白质对EPO具有关键控制作用;(2)利用HIF2A敲除小鼠来模拟人类G537W错义突变,并检测HIF2-()失调在体内的功能后果;以及(3)利用PHD2敲除小鼠和全局条件性PHD2基因敲除小鼠来研究PHD2调节红细胞质量的机制。总而言之,我们预计这些研究将大大增加我们对EPO调节的理解,更广泛地说,我们对哺乳动物氧气感应途径的理解。 与公共健康相关:该项目试图识别和描述导致控制红细胞质量的分子途径,更广泛地说,是对低氧分压的反应。拟议的研究集中在两种蛋白质上,即缺氧诱导因子-2和Pro羟基酶结构域蛋白2,这两种蛋白质与控制决定红细胞质量的激素-红细胞生成素有关。拟议中的实验将对治疗贫血等疾病产生影响,在这些疾病中,红细胞质量异常低。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRANK S LEE其他文献

FRANK S LEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRANK S LEE', 18)}}的其他基金

Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    10295385
  • 财政年份:
    2021
  • 资助金额:
    $ 26.71万
  • 项目类别:
Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    10451588
  • 财政年份:
    2021
  • 资助金额:
    $ 26.71万
  • 项目类别:
Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    10618878
  • 财政年份:
    2021
  • 资助金额:
    $ 26.71万
  • 项目类别:
Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    9751846
  • 财政年份:
    2015
  • 资助金额:
    $ 26.71万
  • 项目类别:
Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    9027529
  • 财政年份:
    2015
  • 资助金额:
    $ 26.71万
  • 项目类别:
Control of Erythropoiesis by the Oxygen Sensor PHD2
通过氧传感器 PHD2 控制红细胞生成
  • 批准号:
    9146882
  • 财政年份:
    2015
  • 资助金额:
    $ 26.71万
  • 项目类别:
High Altitude Adaptation: A Model for Chronic Hypoxia
高海拔适应:慢性缺氧模型
  • 批准号:
    9229060
  • 财政年份:
    2014
  • 资助金额:
    $ 26.71万
  • 项目类别:
High Altitude Adaptation: A Model for Chronic Hypoxia
高海拔适应:慢性缺氧模型
  • 批准号:
    8814276
  • 财政年份:
    2014
  • 资助金额:
    $ 26.71万
  • 项目类别:
High Altitude Adaptation: A Model for Chronic Hypoxia
高海拔适应:慢性缺氧模型
  • 批准号:
    8606645
  • 财政年份:
    2014
  • 资助金额:
    $ 26.71万
  • 项目类别:
Molecular Mechanisms of the Hypoxic Response
缺氧反应的分子机制
  • 批准号:
    8434756
  • 财政年份:
    2010
  • 资助金额:
    $ 26.71万
  • 项目类别:

相似国自然基金

基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 26.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
  • 批准号:
    23K14452
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
  • 批准号:
    23KJ0074
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
  • 批准号:
    10752968
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
  • 批准号:
    10735765
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
  • 批准号:
    10735366
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
  • 批准号:
    10575222
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
  • 批准号:
    10583807
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
A Sample-to-Answer Point-of-Care Diagnostic for Recently Transfused Sickle Cell Anemia Patients in Low Resource Settings
针对资源匮乏地区最近输血的镰状细胞性贫血患者的从样本到答案的护理点诊断
  • 批准号:
    10564553
  • 财政年份:
    2023
  • 资助金额:
    $ 26.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了